These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 6221531)
1. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans. Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531 [No Abstract] [Full Text] [Related]
2. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation. Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196 [TBL] [Abstract][Full Text] [Related]
3. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise. Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226 [No Abstract] [Full Text] [Related]
4. Effects of selective thromboxane synthetase inhibitor and indomethacin on prostacyclin and thromboxane A2 from ischemic canine heart. Ogawa K; Sakai K; Ito T; Watanabe J; Satake T Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():371-6. PubMed ID: 6221548 [No Abstract] [Full Text] [Related]
5. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. Casey LC; Fletcher JR; Zmudka MI; Ramwell PW J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528 [TBL] [Abstract][Full Text] [Related]
7. Clinical study on effect of thromboxane A2 synthetase inhibitor (OKY-046) to clarify the regulation of cerebral blood flow in cerebral thrombosis. Nihei C; Metoki H; Shimanaka Y; Kawahara R; Komatsu O; Oike Y; Kanazawa T; Izawa M; Kaneko H; Hoshi Y Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():953-7. PubMed ID: 2960210 [No Abstract] [Full Text] [Related]
8. Selective thromboxane synthetase inhibitor and ischemic heart disease. Ito T; Ogawa K; Watanabe J; Chen LS; Shikano M; Imaizumi M; Shibata T; Ito Y; Miyazaki Y; Satake T Biomed Biochim Acta; 1984; 43(8-9):S125-32. PubMed ID: 6542777 [No Abstract] [Full Text] [Related]
9. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H Stroke; 1985; 16(2):241-4. PubMed ID: 3883580 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of vessel wall prostacyclin by selective thromboxane synthetase inhibitor OKY 1581. Mehta J; Mehta P; Ostrowski N Prostaglandins Leukot Med; 1983 Sep; 12(1):49-52. PubMed ID: 6356153 [TBL] [Abstract][Full Text] [Related]
11. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats. Gomi T; Ikeda T; Ishimitsu T; Uehara Y Prostaglandins Leukot Essent Fatty Acids; 1989 Sep; 37(3):139-44. PubMed ID: 2608692 [TBL] [Abstract][Full Text] [Related]
12. Formation of thromboxane B2 by platelets and concentrations of thromboxane B2 and 6-keto-prostaglandin F1 alpha in plasma after acute ethanol ingestion. Kangasaho M; Hillbom M; Kaste M; Wuorela H; Vapaatalo H Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():223-8. PubMed ID: 6303086 [No Abstract] [Full Text] [Related]
13. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function. Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of amrinone: role of thromboxane synthetase inhibition. Kinney EL; Draganis T; Luderer JR; Demers LM Prostaglandins Leukot Med; 1983 Jun; 11(2):213-24. PubMed ID: 6576389 [No Abstract] [Full Text] [Related]
15. Selective inhibitor of thromboxane synthetase: pyridine and its derivatives. Miyamoto T; Taniguchi K; Tanouchi T; Hirata F Adv Prostaglandin Thromboxane Res; 1980; 6():443-5. PubMed ID: 7189950 [No Abstract] [Full Text] [Related]
17. Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1 alpha after pharmacological blockade of thromboxane synthetase. Chiabrando C; Castagnoli MN; Noseda A; Fanelli R; Rajtar G; Cerletti C; de Gaetano G Prostaglandins Leukot Med; 1984 Oct; 16(1):79-88. PubMed ID: 6440153 [TBL] [Abstract][Full Text] [Related]
18. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
19. Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. Niwa T; Maeda K; Shibata M; Yamada K Clin Nephrol; 1988 Nov; 30(5):276-81. PubMed ID: 3214971 [TBL] [Abstract][Full Text] [Related]
20. Do prostacyclin and thromboxane play a role in endotoxic shock? Webb PJ; Westwick J; Scully MF; Zahavi J; Kakkar VV Br J Surg; 1981 Oct; 68(10):720-4. PubMed ID: 7025959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]